{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:47:22Z","timestamp":1770252442542,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To identify baseline predictors of anatomical response after intravitreal bevacizumab in polypoidal choroidal vasculopathy (PCV) and to evaluate anatomical and visual outcomes over 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 81 eyes with PCV treated with three consecutive monthly intravitreal bevacizumab injections. Patients were classified as good or poor responders based on optical coherence tomography (OCT) findings at month 3. Baseline demographic, clinical, and imaging parameters were compared between groups, and predictors of poor response were identified using multivariable regression. Visual acuity (VA), central retinal thickness (CRT), subretinal fluid (SRF), and pigment epithelial detachment (PED) height were analyzed within and between groups through month 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty eyes (49.4%) were poor responders and 41 (50.6%) were good responders. Greater baseline SRF height and thinner SFCT were independent predictors of poor response (RR per 100\u00a0\u03bcm: 1.27 and 0.71 respectively; AUC\u2009=\u20090.74). Good responders showed significant VA improvement (0.64\u2009\u00b1\u20090.08 vs. 0.48\u2009\u00b1\u20090.06 logMAR,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and CRT reduction (419.5\u2009\u00b1\u200924.3 vs. 285.5\u2009\u00b1\u200914.1\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at month 3, and these were maintained at month 12. Among good responders, 75% continued bevacizumab injections (non-switch group) and sustained favorable outcomes. In contrast, 86% of poor responders switched to other medications (switch group), achieving significant VA gain, CRT reduction, and further SRF with PED reduction by month 12. The non-switch group required fewer injections (5.8\u2009\u00b1\u20092.5 vs. 7.8\u2009\u00b1\u20093.0 injections;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and achieved longer treatment intervals (11.7\u2009\u00b1\u20099.0 vs. 7.8\u2009\u00b1\u20093.0 weeks;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046) than the switch group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately half of PCV eyes demonstrated a favorable response to bevacizumab monotherapy. Baseline SRF height and SFCT were significant predictors of treatment response. Early assessment after three monthly bevacizumab injections allowed for the differentiation between relatively mild and a more severe disease requiring more frequent and sustained anti-VEGF injections. Switching of anti-VEGFs was associated with improved outcomes in poor responders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00795-x","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:07:00Z","timestamp":1767798420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of response to bevacizumab monotherapy in polypoidal choroidal vasculopathy: a 12-month retrospective study"],"prefix":"10.1186","volume":"12","author":[{"given":"Chinnapat","family":"Montrisuksirikun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supredee","family":"Pongrujikorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuttawut","family":"Rodanant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somanus","family":"Thoongsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supalert","family":"Prakhunhungsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Wongchaisuwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nopasak","family":"Phasukkijwatana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"8","key":"795_CR1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364.","journal-title":"Retina"},{"issue":"7","key":"795_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"795_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"795_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","volume":"31","author":"CK Cheng","year":"2011","unstructured":"Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina. 2011;31(5):846\u201356.","journal-title":"Retina"},{"issue":"3","key":"795_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/eye.2011.324","volume":"26","author":"HJ Cho","year":"2012","unstructured":"Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond). 2012;26(3):426\u201333.","journal-title":"Eye (Lond)"},{"issue":"3","key":"795_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/2474126420946599","volume":"5","author":"PW Feng","year":"2021","unstructured":"Feng PW, Lin J, Sakurada Y, Yannuzzi NA, Smiddy WE, Chilakamarri P, et al. Cost and outcomes analysis of polypoidal choroidal vasculopathy (Aneurysmal type 1 Neovascularization) treatment strategies. J Vitreoretin Dis. 2021;5(3):227\u201331.","journal-title":"J Vitreoretin Dis"},{"issue":"9","key":"795_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u201342.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"795_CR8","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.4103\/ijo.IJO_2985_21","volume":"70","author":"JU Sheth","year":"2022","unstructured":"Sheth JU, Narayanan R, Anantharaman G, Bhende M, Agarwal A, Chawla S, et al. Updated guidelines for the management of polypoidal choroidal vasculopathy: recommendations from the Indian polypoidal choroidal vasculopathy panel and the vitreoretinal society of India. Indian J Ophthalmol. 2022;70(8):3102\u201311.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"795_CR9","first-page":"327","volume":"263","author":"SW Quist","year":"2025","unstructured":"Quist SW, Nab H, Postma M, Amarakoon S, van Asten F, Freriks R. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. Graefes Arch Clin Exp Ophthalmol. 2025;263(2):327\u201345.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"795_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/CEOR.S37458","volume":"4","author":"T Anothaisintawee","year":"2012","unstructured":"Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y. The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand\u2019s pharmaceutical benefit package. Clinicoecon Outcomes Res. 2012;4:361\u201374.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"795_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40942-022-00432-x","volume":"8","author":"FE Zhalka","year":"2022","unstructured":"Zhalka FE, Moisseiev E, Rubowitz A. Polypoidal choroidal vasculopathy-characteristics and response to treatment with bevacizumab in Caucasian patients. Int J Retina Vitreous. 2022;8(1):82.","journal-title":"Int J Retina Vitreous"},{"issue":"8","key":"795_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim H, Lee SC, Kwon KY, Lee JH, Koh HJ, Byeon SH, et al. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1497\u2013503.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"795_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","volume":"40","author":"YC Chang","year":"2020","unstructured":"Chang YC, Cheng CK. Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to Anti-Vascular endothelial growth factor therapy. Retina. 2020;40(7):1403\u201311.","journal-title":"Retina"},{"issue":"1","key":"795_CR14","doi-asserted-by":"publisher","first-page":"21572","DOI":"10.1038\/s41598-021-00904-4","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim JY, Son WY, Kim RY, Kim M, Park YG, Park YH. Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. Sci Rep. 2021;11(1):21572.","journal-title":"Sci Rep"},{"issue":"2","key":"795_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","volume":"155","author":"H Koizumi","year":"2013","unstructured":"Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol. 2013;155(2):305\u201313. e1.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"795_CR16","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1038\/s41598-019-47738-9","volume":"9","author":"N Nagai","year":"2019","unstructured":"Nagai N, Suzuki M, Minami S, Kurihara T, Kamoshita M, Sonobe H, et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep. 2019;9(1):11389.","journal-title":"Sci Rep"},{"issue":"6","key":"795_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721\u201331.","journal-title":"Eye (Lond)"},{"issue":"2","key":"795_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcjo.2021.09.008","volume":"58","author":"M Jimenez-Santos","year":"2023","unstructured":"Jimenez-Santos M, Saenz-Frances F, Calvo-Gonzalez C, Fernandez-Vigo JI, Donate-Lopez J, Lopez-Guajardo L. Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Can J Ophthalmol. 2023;58(2):82\u20139.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"795_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/sjopt.sjopt_73_22","volume":"36","author":"SW Perkins","year":"2022","unstructured":"Perkins SW, Wu AK, Singh RP. Predictors of limited early response to anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration with machine learning feature importance. Saudi J Ophthalmol. 2022;36(3):315\u201321.","journal-title":"Saudi J Ophthalmol"},{"issue":"7","key":"795_CR20","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41433-023-02900-6","volume":"38","author":"A Gigon","year":"2024","unstructured":"Gigon A, Iskandar A, Kasser S, Naso S, Zola M, Mantel I. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration. Eye (Lond). 2024;38(7):1342\u20138.","journal-title":"Eye (Lond)"},{"issue":"1","key":"795_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10792-020-01555-6","volume":"41","author":"R Venkatesh","year":"2021","unstructured":"Venkatesh R, Gadde SGK, Pereira A, Singh V, Sangai S, Sridharan A, et al. Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy. Int Ophthalmol. 2021;41(1):87\u201397.","journal-title":"Int Ophthalmol"},{"issue":"7","key":"795_CR22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00417-020-05051-6","volume":"259","author":"YH Kim","year":"2021","unstructured":"Kim YH, Lee B, Kang E, Oh J. Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1711\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"795_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/IAE.0000000000002902","volume":"41","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Tan CS, Patalauskaite R, Margaron P, Lai TYY. Ranibizumab with or without, verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: predictors of visual and anatomical response in the EVEREST II study. Retina. 2021;41(2):387\u201392.","journal-title":"Retina"},{"issue":"6","key":"795_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/aos.12653","volume":"93","author":"JY Shin","year":"2015","unstructured":"Shin JY, Kwon KY, Byeon SH. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Acta Ophthalmol. 2015;93(6):524\u201332.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"795_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/IAE.0000000000001284","volume":"37","author":"J Baek","year":"2017","unstructured":"Baek J, Lee JH, Lee WK. Clinical relevance of aqueous vascular endothelial growth factor levels in polypoidal choroidal vasculopathy. Retina. 2017;37(5):943\u201350.","journal-title":"Retina"},{"issue":"10","key":"795_CR26","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1167\/iovs.13-13771","volume":"55","author":"CS Tan","year":"2014","unstructured":"Tan CS, Cheong KX. Macular choroidal thicknesses in healthy adults\u2013relationship with ocular and demographic factors. Invest Ophthalmol Vis Sci. 2014;55(10):6452\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"795_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.oret.2020.08.012","volume":"5","author":"Y Song","year":"2021","unstructured":"Song Y, Tham YC, Chong C, Ong R, Fenner BJ, Cheong KX, et al. Patterns and determinants of choroidal thickness in a multiethnic Asian population: the Singapore epidemiology of eye diseases study. Ophthalmol Retina. 2021;5(5):458\u201367.","journal-title":"Ophthalmol Retina"},{"key":"795_CR28","doi-asserted-by":"crossref","unstructured":"Zeng Y, Qiu B, Chen X, Zhang X. OCT and OCTA quantitative metrics for polypoidal choroidal vasculopathy. BMJ Open Ophthalmol. 2025;10(1).","DOI":"10.1136\/bmjophth-2024-002132"},{"issue":"2","key":"795_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.survophthal.2024.10.004","volume":"70","author":"E Sadeghi","year":"2025","unstructured":"Sadeghi E, Valsecchi N, Rahmanipour E, Ejlalidiz M, Hasan N, Vupparaboina KK, et al. Choroidal biomarkers in age-related macular degeneration. Surv Ophthalmol. 2025;70(2):167\u201383.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"795_CR30","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","volume":"34","author":"M Saito","year":"2014","unstructured":"Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina. 2014;34(11):2192\u2013201.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00795-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:41:00Z","timestamp":1770205260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00795-x","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Siriraj Hospital, Mahidol University (COA Si 629\/2023). The requirement for informed consent was waived due to the retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}